全文获取类型
收费全文 | 3972篇 |
免费 | 195篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 94篇 |
妇产科学 | 34篇 |
基础医学 | 919篇 |
口腔科学 | 50篇 |
临床医学 | 203篇 |
内科学 | 778篇 |
皮肤病学 | 144篇 |
神经病学 | 386篇 |
特种医学 | 122篇 |
外科学 | 574篇 |
综合类 | 11篇 |
预防医学 | 74篇 |
眼科学 | 129篇 |
药学 | 243篇 |
中国医学 | 7篇 |
肿瘤学 | 423篇 |
出版年
2023年 | 27篇 |
2022年 | 42篇 |
2021年 | 79篇 |
2020年 | 49篇 |
2019年 | 80篇 |
2018年 | 70篇 |
2017年 | 59篇 |
2016年 | 65篇 |
2015年 | 79篇 |
2014年 | 109篇 |
2013年 | 133篇 |
2012年 | 178篇 |
2011年 | 202篇 |
2010年 | 103篇 |
2009年 | 103篇 |
2008年 | 229篇 |
2007年 | 215篇 |
2006年 | 244篇 |
2005年 | 306篇 |
2004年 | 289篇 |
2003年 | 298篇 |
2002年 | 279篇 |
2001年 | 50篇 |
2000年 | 29篇 |
1999年 | 62篇 |
1998年 | 78篇 |
1997年 | 83篇 |
1996年 | 50篇 |
1995年 | 61篇 |
1994年 | 51篇 |
1993年 | 54篇 |
1992年 | 47篇 |
1991年 | 27篇 |
1990年 | 27篇 |
1989年 | 37篇 |
1988年 | 21篇 |
1987年 | 20篇 |
1986年 | 32篇 |
1985年 | 24篇 |
1984年 | 26篇 |
1983年 | 24篇 |
1982年 | 8篇 |
1981年 | 12篇 |
1980年 | 23篇 |
1979年 | 6篇 |
1978年 | 16篇 |
1977年 | 10篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1969年 | 7篇 |
排序方式: 共有4205条查询结果,搜索用时 15 毫秒
91.
Edgar J. G. Peters Benjamin A. Lipsky ric Senneville Zulfiqarali G. Abbas Javier Aragn‐Snchez Mathew Diggle John M. Embil Shigeo Kono Lawrence A. Lavery Matthew Malone Vilma Urban
i
‐Rovan Suzanne A. Van Asten 《Diabetes/metabolism research and reviews》2020,36(Z1)
The optimal approaches to managing diabetic foot infections remain a challenge for clinicians. Despite an exponential rise in publications investigating different treatment strategies, the various agents studied generally produce comparable results, and high‐quality data are scarce. In this systematic review, we searched the medical literature using the PubMed and Embase databases for published studies on the treatment of diabetic foot infections as of June 2018. This systematic review is an update of previous reviews, the first of which was undertaken in 2010 and the most recent in 2014, by the infection committee of the International Working Group of the Diabetic Foot. We defined the context of literature by formulating clinical questions of interest, then developing structured clinical questions (PICOs) to address these. We only included data from controlled studies of an intervention to prevent or cure a diabetic foot infection. Two independent reviewers selected articles for inclusion and then assessed their relevant outcomes and the methodological quality. Our literature search identified a total of 15 327 articles, of which we selected 48 for full‐text review; we added five more studies discovered by means other than the systematic literature search. Among these selected articles were 11 high‐quality studies published in the last 4 years and two Cochrane systematic reviews. Overall, the outcomes in patients treated with the different antibiotic regimens for both skin and soft tissue infection and osteomyelitis of the diabetic foot were broadly equivalent across studies, except that treatment with tigecycline was inferior to ertapenem (±vancomycin). Similar outcomes were also reported in studies comparing primarily surgical and predominantly antibiotic treatment strategies in selected patients with diabetic foot osteomyelitis. There is insufficient high‐quality evidence to assess the effect of various adjunctive therapies, such as negative pressure wound therapy, topical ointments or hyperbaric oxygen, on infection related outcomes of the diabetic foot. In general, the quality of more recent trial designs are better in past years, but there is still a great need for further well‐designed trials to produce higher quality evidence to underpin our recommendations. 相似文献
92.
93.
Hosen N Ichihara H Mugitani A Aoyama Y Fukuda Y Kishida S Matsuoka Y Nakajima H Kawakami M Yamagami T Fuji S Tamaki H Nakao T Nishida S Tsuboi A Iida S Hino M Oka Y Oji Y Sugiyama H 《British journal of haematology》2012,156(2):213-224
Monoclonal antibody (mAb) drugs are desirable for the improvement of multiple myeloma (MM) treatment. In this study, we found for the first time that CD48 was highly expressed on MM plasma cells. In 22 out of 24 MM patients, CD48 was expressed on more than 90% of MM plasma cells at significantly higher levels than it was on normal lymphocytes and monocytes. CD48 was only weakly expressed on some CD34(+) haematopoietic stem/progenitor cells, and not expressed on erythrocytes or platelets. We next examined whether CD48 could serve as a target antigen for mAb therapy against MM. A newly generated in-house anti-CD48 mAb induced mild antibody-dependent cell-mediated cytotoxicity and marked complement-dependent cytotoxicity against not only MM cell lines but also primary MM plasma cells in vitro. Administration of the anti-CD48 mAb significantly inhibited tumour growth in severe combined immunodeficient mice inoculated subcutaneously with MM cells. Furthermore, anti-CD48 mAb treatment inhibited growth of MM cells transplanted directly into murine bone marrow. Finally and importantly, we demonstrated that the anti-CD48 mAb did not damage normal CD34(+) haematopoietic stem/progenitor cells. These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM. 相似文献
94.
95.
Kunihito Matsumoto Kunihiko Sawada Shigeo Kameoka Yoshiyuki Yonehara Kazuya Honda 《Oral Radiology》2013,29(1):80-86
The temporomandibular joint has many complex anatomical and functional features compared with other joints. Therefore, caution should be exercised in the diagnosis of temporomandibular joint fractures. Although panoramic tomography is widely used for the screening of orofacial trauma as well as other diseases, this modality often overlooks evidence of a condylar fracture. Cone-beam computed tomography is also used for diagnosing orofacial diseases. The purposes of this report are to show the usefulness of cone-beam computed tomography in diagnosing condylar fractures and to describe the imaging features of condylar fractures. 相似文献
96.
97.
98.
Kiyota M Kobayashi T Fuchida S Yamamoto-Sugitani M Ohshiro M Shimura Y Mizutani S Nagoshi H Sasaki N Nakayama R Chinen Y Sakamoto N Uchiyama H Matsumoto Y Horiike S Shimazaki C Kuroda J Taniwaki M 《International journal of hematology》2012,95(5):516-526
We retrospectively investigated the prognostic impact of high-risk cytogenetic abnormalities (CAs) on the outcome of treatment with bortezomib plus dexamethasone (BD) in 43 relapsed/refractory (Rel/Ref) multiple myeloma patients. Fluorescence in situ hybridization (FISH) analysis identified del(13q) in 25 patients, t(4;14) in 14, t(14;16) in 4, 1q21 abnormality in 12 and del(17p) in 2, while G-banding also detected chromosome 13 monosomy (-13) in metaphase spreads from 7 patients. Eighteen of 25 patients with FISH-detected chromosome 13 abnormalities also exhibited other abnormalities. Median observation period was 510 days, and median overall survival (OS) and progression-free survival (PFS) were 912 days and 162 days, respectively. Detection of del(13q), t(4;14), t(14;16) or 1q21 abnormalities by FISH and co-occurrence of chromosome 13 abnormality with other abnormalities were not associated with poorer outcomes. In contrast, detection of -13 by G-banding in metaphase spreads showed significant association with shorter OS, although the overall response rate and PFS were not inferior to those for patients without -13 detected by G-banding. BD therapy may be a potent weapon for overcoming most classical high-risk CAs, while the detection of -13 in metaphase spreads may serve as a predictor of highly progressive disease, even when treated with BD. 相似文献
99.
100.